Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Trellis and OMT Announce Therapeutic Antibody Discovery Collaboration

Published: Tuesday, October 09, 2012
Last Updated: Tuesday, October 09, 2012
Bookmark and Share
Companies will join forces to generate human antibodies against therapeutic targets using OMT’s OmniRat™ platform.

Trellis Bioscience LLC (Trellis) and Open Monoclonal Technology, Inc. (OMT) have announced a new collaboration where the companies will join forces to generate human antibodies against therapeutic targets identified by Trellis and its partners using OMT’s OmniRat™ platform.

Trellis will apply its CellSpot™ antibody screening technology to libraries of OmniRat-generated B cells to discover high affinity, ultra rare antibodies with precisely defined specificity.

Trellis will advance and partner each program and share the deal economics with OMT depending on the stage of development.

Stote Ellsworth, Trellis CEO and President, said: “Trellis’ CellSpot platform has shown in four consecutive programs the unique ability to mine rare, best-in-class therapeutic antibodies directly from human blood. In addition to our native human approach, the collaboration with OMT will leverage Trellis’ powerful multiplexed screening in the context of antibody libraries generated with the OmniRat platform. This will allow Trellis to expand into new therapeutic areas and expand its commercial opportunities, particularly in the field of cancer.”

Dr. Roland Buelow, OMT CEO and Founder, continued: "We are pleased to collaborate with Trellis to capture the synergies of our complementary antibody discovery technologies. This collaboration further illustrates OMT’s ability to partner with a range of companies to produce human therapeutic antibodies.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OMT Announces OmniRat™ Collaboration with CNA Development LLC
OMT to employ its OmniRat™ transgenic animal platform to generate human antibodies.
Monday, December 24, 2012
SCT and OMT Announce Human Antibody Discovery and Development Collaboration
OMT will use OmniRat™ transgenic animal platform to generate human antibodies against a therapeutic target identified by SCT.
Tuesday, December 04, 2012
OMT Announces New Antibody Discovery Program
Open Monoclonal Technology collaborate with Merck KGaA.
Tuesday, July 10, 2012
Scientific News
Leukemia’s Surroundings Key to its Growth
Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Neural Networks Adapt to the Presence of a Toxic HIV Protein
HIV-associated neurocognitive disorders (HAND) afflict approximately half of HIV infected patients.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
Breaking the Brain’s Garbage Disposal
The children’s ataxia gene problem turned out to be not such a big deal genetically — it was such a slight mutation that it barely changed the way the cells made the protein.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!